Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment ...

Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has ...

Earlier this month, the US Food and Drug Administration (FDA) issued new draft guidance regarding their accelerated approval pathway for new drugs ...

Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the ...

CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...